Sun Pharma declares five-year positive results for ILUMYA (tildrakizumab-asmn)
ILUMYA is approved for adults with moderate-to-severe plaque psoriasis and is being evaluated for other possible uses
Sun Pharmaceutical Industries announced that one of its wholly-owned subsidiaries presented positive, five-year Phase 3 data for ILUMYA (tildrakizumab-asmn) from the combined reSURFACE 1 and reSURFACE 2 extension studies. Patients with moderate-to-severe plaque psoriasis who continued to receive ILUMYA through five years of continuous treatment maintained consistent and extensive skin clearance with no new safety issues reported. The data was presented at the 29th European Academy of Dermatology and Venereology (EADV) Virtual Congress.
In an analysis of the pooled reSURFACE 1 and reSURFACE 2 extension studies, patients received ILUMYA 100 mg or 200 mg through five years of continuous treatment. ILUMYA 100 mg is approved in the US, Japan and Australia, and 200 mg is additionally approved under the brand name ILUMETRI™ in Europe. In patients who were treated with ILUMYA 100 mg, clear or almost clear skin (PASI 90) was achieved by 65.9 per cent of patients and 32.8% of patients achieved completely clear skin (PASI 100) at Week 244. The standard goal of treatment, a PASI 75 response, was achieved by 88.7% of patients at Week 244. The long-term analyses also showed absolute PASI <1/<3/<5 scores at Week 28 (50.8%, 85.1% and 96.4%, respectively) were sustained through Week 244 (47.7%, 78.8% and 88.7%, respectively). Absolute PASI scores can provide an indication of the extent of residual disease after treatment. Achievement of an absolute PASI score of <3 has been proposed as comparable to a PASI 90 response, which is equivalent to clear or almost clear skin.3
ILUMYA 100 mg was well-tolerated during the Phase 3 trials. The three adverse reactions that occurred more frequently than placebo and ≥1% in clinical trials were upper respiratory infections (14% vs. 12%), injection site reactions (3% vs. 2%) and diarrhoea (2% vs. 1%). Furthermore, the analysis demonstrated similar exposure-adjusted incidence rates of malignancies throughout five years of study. A majority of malignancies were singular events with similar incidence rates as seen in the general US population.2
ILUMYA is approved for adults with moderate-to-severe plaque psoriasis and is being evaluated for other possible uses.